RE:RE:RE:RE:RE:$14 million US in P2 orders In First halfI usually just lurk here, but read every day and am very appreciative for all of the recent DD many of you have contributed to this board. I know many of us shareholders who usually post elsewhere are very grateful.
On the topic of lack of trust in management being the reason I'd have to agree with the Rock on this one. No doubt they are over paid, but name me one CEO in biotech who isn't. What could they do differently that would get shareholders to earn their trust? In the past year they have won a lawsuit, licensed out their top drug to a big American partner, set themselves up to make bigger deals with that top drug throughout the rest of the world, put $50M on the balance sheet, hired and investment bank to help provide them guidance for the path forward in order to bring the best value for shareholders, revamped and relaunched the WF10 trial, etc...
If they launch a few huge deals in the rest of the world this year for P2% and make an acquisition or two, adding more value to the company will people still be blaming management? What else can they do?
I think it is a few things. a) Liquidity. Having such a low float has its positives and negatives. b) Index listing. They need to get on the Nasdaq and quit screwing around. Having their secondary listing on the pink sheets is a joke. Not sure what they are waiting for with that. c) Get out and sell the company more. It would be nice for management to attend more investment conferences and attract some more analyst coverage. They don't do enough of that in my opinion.
I totally agree with the Rock's statement about value always emerging. By the end of the year if Nuvo has made some good deals, and if the pace of P2% sales marches to/past 10,000 scripts per week in the USA, eventually the market is going to notice this.
I'll admit it is a head scratcher though and I am constantly asking myself if I am missing something here. As it is baffling that this company is valued so low at the moment.